Tag: Novo Nordisk

Obesity Crisis Meets Policy Standstill as Trump Halts Medicare Expansion

Ester Adams
Medicare’s role in weight-loss drug coverage

Trump Administration Reverses Plans to Expand Medicare Coverage for Obesity Drugs The Trump administration has officially halted a Biden-era initiative that aimed to extend Medicare and Medicaid coverage to include obesity drugs, a move set to impact millions of Americans coping with obesity, disproportionately affecting seniors and lower-income groups. While supporters saw the proposed expansion as a progressive step towards tackling one of the nation’s most pressing health challenges, critics have raised concerns over the potential cost burden. Below, we untangle the implications of this decision, exploring its economic, medical,…

Read More

Health insurance could soon cover weight loss drug Wegovy

G. Turner
Health Insurance - Pills wrapped in measuring tape

Novo Nordisk announced that the highly popular drug could have expanded FDA approval in six months. Novo Nordisk recently announced that its headline-making weight loss drug Wegovy could receive expanded US Food and Drug Administration (FDA) approval within six months, opening the door to much more readily available coverage by health insurance plans. The drug is already highly sought-after, but is not necessarily covered by most policies. Novo Nordisk’s chief financial officer Karsten Munk Knudsen said that the company’s application for approval of Wegovy as a cardiovascular disease reduction medication…

Read More